Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Corticalis AS maintains a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. At present, the data shows 1 pending office action across the entire portfolio. This singular point of activity suggests a streamlined prosecution phase or a very specific technical focus within the broader biotech sector.
The prosecution is handled by 1 distinct examiner operating within 1 distinct art unit. This alignment means that the company's current legal efforts are concentrated in a single administrative channel. The presence of 1 distinct art unit indicates that the subject matter remains within a specific niche of Biotechnology & Pharmaceuticals rather than spanning multiple disciplines.
ALAM, AYAAN A is the busiest examiner for Corticalis AS, with 1 busiest examiner pending action. Since this examiner manages the entirety of the current pending workload, the prosecution strategy is dependent on the interactions with this specific individual. This concentration allows for a tailored approach to addressing the examiner's specific concerns or requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, AYAAN A | 1 | 38.8% | +36.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18937758 | Multi-Functional Cleaning and/or Debridement Composition | ALAM, AYAAN A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18937758 | Multi-Functional Cleaning and/or Debridement Composition | ALAM, AYAAN A | 1611 | §103§112DP | Non-Final OA | — | Pending | Nov 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCorticalis AS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ayaan A Alam has the most, with 1 of Corticalis AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
